此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Mobile Geriatric Unit (MGU) to Reduce Hospitalisations in Nursing Home Residents (MGU)

2026年6月8日 更新者:Klaus Faßbender、Universität des Saarlandes

Mobile Geriatric Unit (MGU) to Reduce Hospitalisations in Nursing Home Residents: A Prospective Observational Before-After Study

This prospective observational before-after study evaluates the impact of a Mobile Geriatric Unit (MGU) on hospitalisation rates among nursing home residents. The study includes a 12-month control phase with usual care followed by a 12-month intervention phase during which the MGU is implemented. The MGU provides advanced on-site diagnostics and telemedicine-supported specialist consultation within nursing homes.

研究概览

详细说明

This prospective observational before-after study evaluates the impact of a Mobile Geriatric Unit (MGU) on hospitalisation rates among nursing home residents in Saarland, Germany. The study includes a 12-month control phase with usual care followed by a 12-month intervention phase with MGU implementation in 46 nursing homes.

The MGU provides on-site advanced diagnostics (CT, X-ray, ultrasound, ECG, EEG, and laboratory testing) supported by telemedicine consultation with hospital specialists. A physician and radiology technician perform diagnostics in the nursing home, with results communicated to the general practitioner for treatment decisions within 48 hours.

Usual care involves hospital referral and in-hospital diagnostics. The intervention aims to reduce avoidable hospital admissions by providing diagnostics and specialist input directly in the nursing home.

The primary outcome is hospital admissions per person-year. Secondary outcomes include mortality, functional and cognitive status, quality of life (EQ-5D-5L), complications, healthcare costs, and 30-day hospitalisation-free survival.

Eligible participants are nursing home residents with consent or proxy consent; those requiring immediate hospitalisation are excluded.

Data are obtained from routine care and medical records, MGU documentation, structured assessments, and follow-up. Multilevel Poisson regression and interrupted time series analysis will be used.

The study was approved by the Ethics Committee of Saarland (AZ 159-21) and conducted in accordance with the Declaration of Helsinki.

研究类型

观察性的

注册 (估计的)

4907

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Saarland
      • Homburg、Saarland、德国、66421
        • Nursing Homes in Saarland

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

Residents of participating nursing homes

描述

Inclusion Criteria:

  • Residents of participating nursing homes
  • Informed consent from participant or legal representative

Exclusion Criteria:

  • Acute life-threatening conditions requiring immediate hospitalisation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Control Phase (Usual Care)
Usual care including general practitioner (GP) referral, hospital transport, and in-hospital diagnostics and treatment.
Intervention Phase (MGU)
On-site diagnostic evaluation using the Mobile Geriatric Unit with broad diagnostic capabilities followed by teleconsultation and further treatment by the general practitioner.
The MGU is a mobile diagnostic unit providing on-site diagnostics in nursing homes. It includes a 32-slice (64 slice reconstruction) whole body CT scanner, digital X-ray, portable ultrasound, ECG, EEG, and point-of-care laboratory diagnostics. A physician and radiology technician perform diagnostics on-site. Results are transmitted via telemedicine to hospital specialists and communicated to the general practitioner for treatment decisions within 48 hours.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Hospital admissions per person-year
大体时间:Up to 24 months
Number of inpatient hospital admissions, excluding elective admissions.
Up to 24 months

次要结果测量

结果测量
措施说明
大体时间
Mortality
大体时间:Day 180
Mortality
Day 180
Functional status; mobility: modified Rankin Scale (mRS)
大体时间:Day 180

Modified Rankin Scale (mRS):

0: No symptoms

  1. No significant disability
  2. Slight disability
  3. Moderate disability
  4. Moderately severe disability
  5. Severe disability
  6. Death

Minimum value: 0 (best outcome) Maximum value: 6 (worst outcome)

Day 180
Functional status; frailty: Clinical Frailty Scale
大体时间:Day 180

Clinical Frailty Scale (as according to Moorhouse and Rockwood*):

  1. very fit
  2. well
  3. managing well
  4. apparently vulnerable
  5. mildly frail
  6. moderately frail
  7. severely frail
  8. very severely frail
  9. terminally ill

Minimum value: 1 (best outcome) Maximum value: 9 (worst outcome)

* Moorhouse P, Rockwood K. Frailty and its quantitative clinical evaluation. J R Coll Physicians Edinb 2012; 42: 333-40

Day 180
Cognitive status
大体时间:Day 180
The cognitive performance assessment is carried out through subjective evaluation by the nursing home's nursing staff at day 180.
Day 180
Healthcare costs
大体时间:Day 360
Hospitalisation, transport, and MGU costs
Day 360
30-day hospitalisation-free survival
大体时间:Day 30
Hospitalisation-free survival at day 30
Day 30
Quality of life (EQ-5D-5L)
大体时间:Day 180

EQ-5D-5L is a standardised measure of health-related quality of life developed by the EuroQol Group and assesses health status in terms of five dimensions of health. The five levels in each dimension are worded as (1) 'not /no problems', (2) 'slight problems', (3) 'moderate problems', (4) 'severe problems' and (5) 'unable to' (mobility, self-care, usual activities), 'extreme' (pain/depression), or 'extremely' (anxiety/depression).

Minimum value: 1 (best outcome) Maximum value: 5 (worst outcome)

Day 180

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Klaus Fassbender, Professor、Universität des Saarlandes

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2027年9月30日

研究完成 (估计的)

2028年3月1日

研究注册日期

首次提交

2026年5月26日

首先提交符合 QC 标准的

2026年6月2日

首次发布 (实际的)

2026年6月9日

研究记录更新

最后更新发布 (实际的)

2026年6月10日

上次提交的符合 QC 标准的更新

2026年6月8日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • MGU

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅